Jobs / United States / Sanofi US Services INC
Director, Marketing – MPS I and ASMD
Sanofi US Services INC · 🇺🇸 Cambridge, MA
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 47 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 29 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Sanofi US Services INC paid sponsored hires in similar roles2 certified filings for “Associate Director” (Regulatory Affairs Managers) in MA: $147k–$147k, median $147k. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Sanofi US Services INC
The US Department of Labor certified 47 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 29 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Sanofi US Services INC →
About the role
Job title : Director, Marketing – MPS I and ASMD • Location: Cambridge, MA About the Job The Director, Marketing – MPS I and ASMD is the brand strategy lead for Sanofi's ASMD and MPS I disease portfolio, encompassing Xenpozyme® (olipudase alfa) for Acid Sphingomyelinase Deficiency (ASMD) and Aldurazyme® (laronidase) for Mucopolysaccharidosis I (MPS I). This role owns brand strategy, campaign and messaging platform, brand planning process, and core team governance for these two disease areas, and serves as the primary U.S.-to-Global commercial partner for both brands. The Director directly manages and develops a team of three — a Patient Experience Marketer, an HCP Experience Marketer, and a PharmD Fellow bringing strong people leadership, strategic thinking, and rare disease commercial expertise to the role. A defining priority of this position is leading the transition of both the ASMD and MPS I brand away from traditional agency-dependent models toward a fully AI/digital marketing platform. This includes building internal digital capabilities, owning content and campaign production digitally, and systematically reducing reliance on external creative and media agencies over time — positioning this portfolio as a model for digital-first, agile brand marketing within Sanofi Rare Disease. Join the team transforming care for people with immune challenges, rare diseases, cancers, and Specialty Care neurological conditions. In Specialty Care, you’ll help deliver breakthrough treatments that bring hope to patients with some of the highest unmet needs. About Sanofi We’re an R&D-driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. Our deep understanding of the immune system – and innovative pipeline – enables us to invent medicines and vaccines that treat and protect millions of people around the world. Together, we chase the miracles of science to improve people’s lives. Main Responsibilities Brand Strategy – ASMD & MPS I Portfolio • Own the U.S. brand strategy for Xenpozyme and Aldurazyme, ensuring each brand maintains compelling, differentiated, and commercially sound strategic positioning • Develop and maintain the strategic framework for the ASMD and MPS I portfolio, including portfolio prioritization, lifecycle management, and competitive response strategies • Ensure brand strategies are grounded in data, customer insights, competitive intelligence, and clinical data, addressing the full patient journey • Anticipate market dynamics and proactively evolve brand positioning to reflect the evolving ASMD and MPS I treatment landscapes Digital-First Brand Campaign & Messaging • Own the brand campaign and messaging platform for ASMD and MPS I, ensuring compelling, differentiated, and compliant brand narratives for both HCP and patient audiences • Lead the development and evolution core messaging, visual identity, and campaign architecture for Xenpozyme and Aldurazyme • Drive the transition to a no-agency, fully in-house digital marketing model, building internal digital production capabilities, establishing in-house content creation workflows, and architecting a digital-first campaign infrastructure • Ensure campaign and messaging alignment across all digital channels and tactics, leveraging internal teams to execute with speed and precision • Champion a culture of digital innovation, testing, and optimization across the ASMD and MPS I brand teams Brand Plan Leadership • Lead the annual brand planning process for the ASMD and MPS I portfolio, including situation analysis, strategic imperatives, tactical planning, and resource allocation • Integrate digital transformation milestones and in-house capability-building objectives into annual bra